These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 33477569)

  • 1. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
    Bansal D; Reimers MA; Knoche EM; Pachynski RK
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
    Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
    Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
    Lanka SM; Zorko NA; Antonarakis ES; Barata PC
    Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances.
    Movassaghi M; Chung R; Anderson CB; Stein M; Saenger Y; Faiena I
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
    Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
    Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
    Marshall CH; Antonarakis ES
    Cancer Treat Res Commun; 2020 Jan; 23():100164. PubMed ID: 31978677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Gamat-Huber M; Jeon D; Johnson LE; Moseman JE; Muralidhar A; Potluri HK; Rastogi I; Wargowski E; Zahm CD; McNeel DG
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG; Agarwal N; Araujo JC; Sonpavde G
    Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Past, Current, and Future of Immunotherapies for Prostate Cancer.
    Boettcher AN; Usman A; Morgans A; VanderWeele DJ; Sosman J; Wu JD
    Front Oncol; 2019; 9():884. PubMed ID: 31572678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current Trend of CAR-T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1038-1042. PubMed ID: 38035830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.
    López-Campos F; Gajate P; Romero-Laorden N; Zafra-Martín J; Juan M; Hernando Polo S; Conde Moreno A; Couñago F
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in bio-immunotherapy for castration-resistant prostate cancer.
    Lin C; Chen Y; Shi L; Lin H; Xia H; Yin W
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):13451-13458. PubMed ID: 37460807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.